| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d71b81389596ab9801ddb1dcd213db5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_898bd61ef8df09530a851ccd7ad0a5d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60867eeac051ca001adebb32120e016b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| filingDate |
2012-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_745d5a69c319245345e5800d7fcd160d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78bacc2239694973d3c7682a33a7b8d7 |
| publicationDate |
2012-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012139068-A2 |
| titleOfInvention |
Co-administration of arsenic compounds and anti-herpes virus anti-virals |
| abstract |
It has now been discovered that arsenic induces herpesviruses latent in infected cells to reactivate to the lytic stage. Herpes viruses in the lytic stage activate anti-herpes virus anti¬ viral agents. Co-administration of arsenic compounds and anti-herpesviral agents to a population of cells infected with a herpes virus results in the death of the cells and inhibits proliferation of the virus. The invention is therefore useful for reducing a subject's population of cells infected with herpes viruses, particularly Epstein-Barr virus. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014185973-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9669036-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021083964-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3815699-A1 |
| priorityDate |
2011-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |